CorMedix Inc. - FORM 8-K - EX-99.1

Attached files

file	filename
8-K - CURRENT REPORT - CorMedix Inc.	crmd_8k.htm

EXHIBIT 99.1

NYSE MKT: CRMD

August 2013

Company Overview

Forward Looking Statements

This presentation contains certain statements that constitute forward-looking statements within the
meaning of the federal securities laws. Statements that are not historical facts, including statements
about our beliefs and expectations, are forward-looking statements. These statements are not
guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to
predict. The forward looking statements in this presentation include statements about our business,
including commercialization plans and potential markets for our products and product candidates,
clinical trials, potential indications for our product candidates, development timelines, regulatory
timelines and future events that have not yet occurred. Pharmaceutical and medical device
development inherently involves significant risks and uncertainties, including the risks outlined in “Risk
Factors” in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on
March 27, 2013 and in “Risk Factors” in our Quarterly Reports on Form 10-Q filed with the Securities
and Exchange Commission on May 15 and August 14, 2013. Our actual results may differ materially
from our expectations due to these risks and uncertainties, including, but not limited to, our
dependence on the success of our lead product candidate, and factors relating to commercialization
and regulatory approval thereof, ability to raise sufficient capital, retaining our stock’s listing on the
NYSE MKT, research and development activities, intellectual property protection, competition,
industry environment, and other matters. Any forward-looking statements included in this presentation
are based on information available to us on the date of this presentation. We undertake no obligation
to update or revise any forward-looking statement, whether as a result of new information, future
events or otherwise.

CorMedix: A Catheter Care Company

What is Neutrolin®?

Why Neutrolin®?

Neutrolin®

Strategic Pillars

Key Activities:

•Successful launch in Germany and Austria

• Experienced sales team targets early
adopters

• Increase healthcare provider awareness

•Negotiate Partner Arrangements

• Position Neutrolin® strategically

§ Pricing

§ Understand payer reimbursement policies

Neutrolin®

Strategic Pillars

Key Activities:

•Expansion into oncology, ICU, Total
Parenteral Nutrition, and peritoneal
dialysis fields

•Submission of required data to TUV

•Develop target list of physicians and
expand the sales force

Neutrolin®

Strategic Pillars

Key Activities:

•Identify and prioritize key countries

•Identify best sales partners in key
countries

§ Screening/due diligence / deal
negotiations conducted with
country and regional specific
advisors

•Complete agreements

•Monitor product positioning and
coordinate manufacturing capacity

Neutrolin®

Strategic Pillars

Potential Opportunity for Consideration:

• U.S. FDA discussions (pre-IND meeting, timelines)

• Clinical trial requirements by FDA

§ Patient population size

§ Duration

• Clinical trial execution decision

§ Strategic partner

§ Go alone if sufficient internal funding

Neutrolin®

Strategic Pillars

Business Development to Target Countries with
High Catheter Use and Favorable Reimbursement

• Major Countries: U.S., Japan,
China, Brazil, Germany, Canada

Source: Derived from USRDS, 2011, and Dialysis Outcomes and Practice Pattern Study (DOPPS) Annual
Report 2010, and Canadian Institute for Health Information, Canadian Organ Replacement Registry

Process in Place to Select Best Sales Partner

Large Worldwide Hemodialysis Opportunity

European Union Sales Partnerships:

• 91,000 hemodialysis catheter patients

• 28 countries

U.S. Clinical Development Funding and Sales Partnerships

• 104,000 hemodialysis catheter patients

Top 5 Hemodialysis markets: U.S., Japan, China, Brazil, Germany.

Source: Derived from USRDS, 2011, and Grassman, Neprol. Dial. Transplant (Dec 2005) 20 (12):25-87-2593, and

Dialysis Outcomes and Practice Pattern Study (DOPPS) Annual Report 2010, CorMedix estimates

Asia/Middle East/North and South America Sales Partnerships

• 106,000 hemodialysis catheter patients

• China, Japan, Korea, Saudi Arabia, Brazil, Canada

Opportunity to Grow with Label Expansion into other

Catheter Applications

European Union Sales Partnerships:

• 145,600 catheter patients

• 28 countries

U.S. Clinical Development Funding and Sales Partnerships

• 124,800 catheter patients

Other catheter applications: chemotherapy, intensive care, total parenteral nutrition.

Source: CorMedix estimates based on hemodialysis catheter patients derived from USRDS, 2011, and Grassman,

Neprol. Dial. Transplant (Dec 2005) 20 (12):25-87-2593, and Dialysis Outcomes and Practice Pattern Study (DOPPS)

Asia/Middle East/North and South America Sales Partnerships

• 106,000 catheter patients

• China, Japan, Korea, Saudi Arabia, Brazil, Canada

Significant Near Term Hemodialysis Opportunity in E.U.

Initially CorMedix will target the Hemodialysis market:

• E.U. : 91,000 hemodialysis catheter patients

These patients represent ~14.2 million HD sessions per year

(91,000 HD catheter patients * 3 weekly dialysis sessions/week * 52 weeks per year = 14.2 million)

Potential Hemodialysis Market Size in E.U. :

USD $40 - $80 million

Source: Derived from USRDS, 2011, and Grassman, Neprol. Dial. Transplant (Dec 2005) 20 (12):25-87-2593, and

Dialysis Outcomes and Practice Pattern Study (DOPPS)

…..and Even Greater Opportunity in the Long Term
with Other Key Countries and an Expanded Label

Hemodialysis and Expanded Label market:

• E.U.: 236,600 catheter patients

• Other Key Countries: 212,000 catheter patients

Long Term Potential Market Size in E.U. and Other Key Countries
for Hemodialysis and Expanded Label:

USD $180 - $340 million

Top 5 Hemodialysis markets: U.S., Japan, China, Brazil, Germany.

Source: Derived from USRDS, 2011, and Grassman, Neprol. Dial. Transplant (Dec 2005) 20 (12):25-87-2593, and

Dialysis Outcomes and Practice Pattern Study (DOPPS)

Option to Enter the United States with Strategic
Partnerships or Internal Funding

U.S. Hemodialysis and Expanded Label market:

• 228,800 catheter patients

Long Term Potential Market Size in U.S. for Hemodialysis and
Expanded Label:

USD $140 - $270 million

Top 5 Hemodialysis markets: U.S., Japan, China, Brazil, Germany.

Source: Derived from USRDS, 2011, and Grassman, Neprol. Dial. Transplant (Dec 2005) 20 (12):25-87-2593, and

Dialysis Outcomes and Practice Pattern Study (DOPPS)

IP Status Update

• Global Patent Estate - 17 issued patents provide protection
through 2019-2025

§ Freedom to Operate

§ Proprietary

Ø Sodemann: A method of inhibiting or preventing infection and blood
coagulation as a medical prosthetic device using a pharmaceutical
composition comprising taurolidine and citric acid

Ø Prosl: A locking solution comprising a taurinamide derivative, a
biologically acceptable acid and low concentration heparin

Ø Polaschegg: gel technology with taurolidine

• Planned additional filings under prosecution to extend
protection

Neutrolin®

Strategic Pillars

http://www.CorMedix.com/

NYSE MKT: CRMD

August 2013

Thank You!

CorMedix Inc. - FORM 8-K - EX-99.1 - August 26, 2013

Attached files

CorMedix Inc. Reports